Cargando…

Advances in the use of PARP inhibitor therapy for breast cancer

Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described. BRCA1 and BRCA2 (Breast Cancer) proteins are involved in homologous recombination repair (HRR), wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCann, Kelly E, Hurvitz, Sara A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089618/ https://www.ncbi.nlm.nih.gov/pubmed/30116283 http://dx.doi.org/10.7573/dic.212540

Ejemplares similares

Harnessing the immune system in the battle against breast cancer
por: Nakasone, Elizabeth S, et al.
Publicado: (2018)

Recent advancements in PARP inhibitors-based targeted cancer therapy
por: Zhou, Ping, et al.
Publicado: (2020)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
por: Franchet, Camille, et al.
Publicado: (2021)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
por: Chen, Hongjie, et al.
Publicado: (2023)

Advances in using PARP inhibitors to treat cancer
por: Kummar, Shivaani, et al.
Publicado: (2012)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

PARP inhibitors in the management of breast cancer: current data and future prospects
por: Livraghi, Luca, et al.
Publicado: (2015)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
por: Gonçalves, Anthony, et al.
Publicado: (2020)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
por: Ström, Cecilia E., et al.
Publicado: (2012)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials
por: Xia, Mingyue, et al.
Publicado: (2021)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
por: Sun, Ximu, et al.
Publicado: (2021)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
por: Shao, Nan, et al.
Publicado: (2019)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
por: Nerone, Marta, et al.
Publicado: (2023)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Epigenetic Insights on PARP-1 Activity in Cancer Therapy
por: Pinton, Giulia, et al.
Publicado: (2022)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b6jgrje5saki23rrqr9vmq4uio